Effects of OCTA-guided PDT in Acute CSC

Peking University People's Hospital23 enrolled

Overview

OCTA-guided PDT is as safe and effective as ICGA-guided PDT in the treatment of acute central serous chorioretinopathy. Or OCTA-guided PDT is more effective than ICGA-guided PDT in the treatment of acute central serous chorioretinopathy, safe as well.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Central Serous Chorioretinopathy Tomography, Optical Coherence

Interventions

OCTA-guided Photodynamic therapyPROCEDURE

Half-dose photodynamic therapy using verteporfin under the guidance of OCTA

ICGA-guided Photodynamic therapyPROCEDURE

Half-dose photodynamic therapy using verteporfin under the guidance of ICGA

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA * Presence of SRF and/or serous pigment epithelial detachment on OCT * Presence of abnormal dilated choroidal vasculature in ICGA Exclusion Criteria: * Patients with other ocular conditions commonly associated with SRF, such as choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), diabetic retinopathy, retinal vascular occlusion, Coat's disease * Any disease that may affect the quality of imaging (quality of OCTA images \< 6), such as cataract, high myopia or nystagmus * History of ocular surgeries including retinal laser * Pregnancy * Any uncontrolled systemic disease * Any condition rendering patients intolerable to image acquisition

Locations (1)

People's Hospital of Peking University

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Number of patients with subretinal fluid resolution on OCT after PDT of two groups

Time frame: 3 months

Secondary Outcomes

Number of patients with leakage point resolution on FFA after PDT of two groups

Time frame: 3 months

Number of recurrent CSC after PDT of two groups

Time frame: 3 months

BCVA (best corrected visual acuity) at every follow-up of two groups

Time frame: 1 month, 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.